Your browser doesn't support javascript.
loading
Optimal Hemodynamics and Risk of Severe Outcomes Post-Left Ventricular Assist Device Implantation.
Rosenbaum, Andrew N; Ternus, Bradley W; Stulak, John M; Clavell, Alfredo L; Schettle, Sarah D; Behfar, Atta; Jentzer, Jacob C.
Afiliación
  • Rosenbaum AN; From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
  • Ternus BW; William J von Liebig Center for Transplantation and Clinical Regeneration. Mayo Clinic, Rochester, Minnesota.
  • Stulak JM; Department of Medicine, Division of Cardiovascular Medicine, University of Wisconsin, Madison, Wisconsin.
  • Clavell AL; Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.
  • Schettle SD; From the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
  • Behfar A; William J von Liebig Center for Transplantation and Clinical Regeneration. Mayo Clinic, Rochester, Minnesota.
  • Jentzer JC; Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.
ASAIO J ; 68(3): 325-332, 2022 03 01.
Article en En | MEDLINE | ID: mdl-35213881
ABSTRACT
Data on pre-implant hemodynamic optimization before continuous flow left ventricular assist device placement (CF-LVAD) with respect to patient-centered outcomes remain limited. Consecutive patients undergoing CF-LVAD implant between 2007 and 2017 were identified. Hemodynamic variables, trends, and laboratory studies were evaluated pre-LVAD implant in a logistic regression model to identify predictors of the primary composite endpoint the need for right ventricular assist device therapy, the requirement for hemodialysis at 90 days, and 30-day mortality. Multivariate modeling identified three variables significantly associated with the primary endpoint right ventricular stroke work index (RVSWI), right atrial pressure (RAP), and blood urea nitrogen (BUN); all immediately pre-LVAD, p < 0.01. Optimal dichotomization points were 500 mmHg*ml*m-2, 12 mmHg, and 40 mg/dL. The three-component model identified an AUC of 0.77 (p < 0.0001) for the composite endpoint. Optimization of 2/3 parameters, 1/3, and 0/3 was associated with odds ratios of 3.5 (95% CI, 1.1-11.7), 7.2 (95% CI, 2.1-24.2), and 20.6 (95% CI, 5.3-80.6), respectively, relative to those patients who were fully optimized (3/3 parameters). The number of optimized parameters was also associated with 1-year overall survival (p = 0.02). Low RVSWI, high RAP, and high BUN were independently associated with adverse outcomes after the CF-LVAD implant, demonstrating a stepwise association with severe postimplant adverse events.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Corazón Auxiliar / Disfunción Ventricular Derecha / Insuficiencia Cardíaca Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: ASAIO J Asunto de la revista: TRANSPLANTE Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Corazón Auxiliar / Disfunción Ventricular Derecha / Insuficiencia Cardíaca Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: ASAIO J Asunto de la revista: TRANSPLANTE Año: 2022 Tipo del documento: Article